While the U.S. is busy debating drug price caps, Alkem decided to flex margins, pump up domestic growth, and quietly sneak into MedTech. Q1 FY26 wasn’t just strong—it was Alkem announcing, “We’re not just about antibiotics anymore, folks.” With biosimilars, CDMO, and chronic therapy ambitions, the company suddenly looks more like a pharma buffet than a generics diner. But wait—there’s U.S. price erosion, tariff threats, and ₹750 Cr capex to chew on. Let’s unwrap this capsule slowly—it’s loaded.
PAT ₹664 Cr (+21.8%) – Bottom line stronger than gym bros on creatine.
3. Management’s Key Commentary
Quote: “Disciplined execution and pivot to value-accretive products boosted performance.” (Translation: We finally stopped selling only cheap antibiotics.)
Quote: “India outperformed IPM by 120 bps, growing across 7 key therapies.” (Translation: Doctors love prescribing our pills more than competition’s freebies.)
Quote: “MedTech business started with ₹2.5 Cr, aiming ₹40–50 Cr ARR by FY26-end.” (Translation: Right now pocket money, later hopefully pocket rocket.)
Quote: “Capex of ₹750 Cr for FY26, mostly on biotech/CDMO.” (Translation: Burning cash today, praying for biologics jackpot tomorrow.)
Quote: “R&D spend guided at 4.5–5% of revenue.” (Translation: Filing drugs = filing expenses, but still cheaper than Bollywood VFX.)
Quote: “Margins will improve 100 bps annually till mid-20s.” (Translation: We’re on a slow but steady keto diet.)
4. Numbers Decoded
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹3,371 Cr
+11.2%
Beating IPM growth, led by branded India sales.
India Sales – The Star
₹2,266 Cr
+12%
Branded Generics carried the quarter on its back.
U.S. Sales – The Problem Kid
₹698 Cr
+8.8%
Grew, but 3-4% price erosion still stings.
Non-U.S. Intl – The Explorer
₹356 Cr
+9.1%
Quietly scaling outside America.
EBITDA – The Cushion
₹739 Cr
+21.4%
Margin lifted by API softness + India mix.
EBITDA Margin – The Flex
21.9%
+180 bps
Crossing 20% for a pharma feels like IPL win.
PAT – The Survivor
₹664 Cr
+21.8%
Profit joined the margin party.
R&D – The Expense Pill
₹118 Cr
3.5% sales
Will ramp to 5% later—more filings = more bills.
5. Analyst Questions
Q: Will FY26 guidance be upgraded after this blockbuster Q1? A: Too early, let’s wait. (Translation: Don’t jinx it, bro. One quarter ≠ whole year.)
Q: MedTech breakeven timeline? A: FY28. (Translation: Till then, enjoy ₹40–50 Cr revenue with ₹40–50 Cr losses.)
